Research Corporation Technologies, Inc.

Other

Alimunne, L.l.c.

Andrew I Lazarovits

Sibrand Poppema

A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens, including the CD45RB epitope.

Use of anti-CD45 leukocyte antigen antibodies for immunomodulation

A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens.

Compositions comprising anti-CD45RB antibodies are provided for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases.

Pharmaceutical compositions comprising anti-CD45RB antibodies for the

Compounds and methods are described for the differential inhibition of tyrosine phosphorylation of phospholipase C-.gamma.1 for the prevention or reversal of transplant rejection as well as therapy for autoimmune diseases. Methods for the treating or preventing tissue or organ transplant rejection and methods for treating an autoimmune disease comprising the administration of monoclonal antibodies that specifically bind to the CD45RB epitope of the CD45RB isoform are disclosed.

Growing community of inventors

London, Canada

Andrew I Lazarovits